Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- EFPIA, EC Embark on Joint Drug Discovery Research Project
April 16, 2007
- Study Group on Early Approval of Safe, Effective Drugs
April 16, 2007
- 90% of Doctors Predict Increases in Cerebro-, Cardiovascular Diseases: Prof. Teramoto
April 16, 2007
- Ordinary Single-Dose Tox Studies Sufficient to Initiate MD Studies: Symposium
April 16, 2007
- Daiichi Sankyo Sets Out To Become a "Global Pharma Innovator"
April 16, 2007
- R&D NEWS IN BRIEF
April 16, 2007
- Mochida to Increase MRs to 750 by FY2009
April 16, 2007
- TOPICS／Abilify Receives PSJ Award: Otsuka
April 16, 2007
- Industry's Highest Growth Rate Recorded Twice in 2 Years: NBI
April 16, 2007
- Use of 9 Reagents for Pancreatic Islet Transplantations Restricted
April 16, 2007
- Janssen's Sales Drop 11.8% Due to NHI Price Cuts
April 16, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 16, 2007
- BUSINESS NEWS IN BRIEF
April 16, 2007
- 26 Complaints Received Regarding Supply of Generics in 1 Year
April 16, 2007
- Abnormal Behavior Reported from 128 Patients after Taking Tamiflu: Korosho
April 16, 2007
- PSJ Luncheon Seminar
April 16, 2007
- Antidiabetic Drug Market Predicted to Increase to ¥490 Billion in 2015
April 9, 2007
- R&D NEWS IN BRIEF
April 9, 2007
- Mochida to Distribute Remodulin in Japan
April 9, 2007
- Alfresa Aims to Build Nationwide Network for OTC Drugs: President Watanabe
April 9, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…